Source: Eur Respir J 2013; 42: 1595-1603
Disease area: Paediatric lung diseases, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Elemraid Mohamed A., Sails Andrew D., Eltringham Gary J.A., Perry John D., Rushton Stephen P., Spencer David A., Thomas Matthew F., Eastham Katherine M., Hampton Fiona, Gennery Andrew R., Clark Julia E.. Aetiology of paediatric pneumonia after the introduction of pneumococcal conjugate vaccine. Eur Respir J 2013; 42: 1595-1603

Member's Comments

No comment yet.

Related content which might interest you: Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia Source: Eur Respir J 2015; 45: 1632-1641 Year: 2015 The remaining challenges of pneumococcal disease in adults Source: Eur Respir Rev 2012; 21: 57-65 Year: 2012 Impact of introducing the 10-valent pneumococcal conjugate vaccine on childhood hospitalizations for bacterial pneumonia in Brazil Source: Annual Congress 2013 –Paediatric respiratory epidemiology: bronchiolitis and asthma Year: 2013 Effectiveness of the pneumococcal polysaccharide vaccine in preventing pneumonia in the elderly Source: Eur Respir J 2010; 36: 608-614 Year: 2010 Effectiveness of a 23-valent pneumococcal polysaccharide vaccine and a 13-valent pneumococcal conjugate vaccine among the elderly with chronic respiratory diseases Source: International Congress 2018 – Pneumonia: from the community to the intensive care unit Year: 2018 Impact of pneumococcal vaccination in children in the distribution of serotypes in bacteriemic pneumococcal pneumonia in adults Source: International Congress 2017 – Discussion of vaccines, biomarkers and risk factors analysis   Year: 2017 Role of pneumococcal vaccine on the incidence of childhood empyema Source: Breathe 2010; 6: 366-367 Year: 2010 Should pneumococcal vaccines be used to prevent LRTI? Source: Annual Congress 2009 - PG1 EU GRACE Network Full-day Course: vaccination and preventive measures for LRTIs in the community: what’s new? Year: 2009 Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands Source: Eur Respir J 2015; 46: 1407-1416 Year: 2015 Impaired response to 13-valent pneumococcal conjugate vaccine (PCV13) in children with recurrent respiratory infections and chronic cough. Source: Virtual Congress 2021 – Paediatric respiratory infections: chronic infection, vaccination and lung function Year: 2021 Introduction of the 13-valent pneumococcal conjugate vaccine in an isolated pneumococcal vaccine-naïve indigenous population Source: Eur Respir J 2016; 48: 1492-1496 Year: 2016 Protective effect of pneumococcal vaccine against death by pneumonia in elderly subjects Source: Eur Respir J 2005; 26: 1086-1091 Year: 2005 The pathophysiology of pneumococcal pneumonia Source: Eur Respir Monogr 2014; 63: 42-63 Year: 2014 Effectiveness data on prevention of COPD exacerbations with 13-valent pneumococal conjugate vaccine (PCV13) Source: International Congress 2017 – Discussion of vaccines, biomarkers and risk factors analysis   Year: 2017 No preventive effects of 23-valent pneumococcal polysaccharide vaccine in patients with chronic renal failure Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment Year: 2016 A longitudinal analysis of pneumococcal vaccine serotypes in pneumonia patients in Germany Source: Eur Respir J, 59 (2) 2102432; 10.1183/13993003.02432-2021 Year: 2022 Influence of pneumococcal serotype group on outcome in adults with bacteraemic pneumonia Source: Eur Respir J 2010; 36: 1073-1079 Year: 2010